{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:42:15Z","timestamp":1789717335909,"version":"4.0.1"},"reference-count":26,"publisher":"Wiley","license":[{"start":{"date-parts":[[2012,8,29]],"date-time":"2012-08-29T00:00:00Z","timestamp":1346198400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pain Research and Treatment"],"published-print":{"date-parts":[[2012,8,29]]},"abstract":"<jats:p>We summarize efficacy and safety findings from 4 double-blind, placebo-controlled, 12-week studies and 1 open-label, uncontrolled, 34-week maintenance-of-effect (MOE) study that examine duloxetine 40 and 60 mg once daily (QD) in patients with diabetic peripheral neuropathic pain (DPNP). In all placebo-controlled studies, duloxetine showed significantly (<mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M1\"><mml:mrow><mml:mi>P<\/mml:mi><mml:mo>\u2264<\/mml:mo><mml:mn>.01<\/mml:mn><\/mml:mrow><\/mml:math>) greater reduction in pain severity (weekly mean of 24-hour average pain severity ratings, primary outcome measure) compared with placebo. In all placebo-controlled studies, duloxetine showed significantly (<mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M2\"><mml:mrow><mml:mi>P<\/mml:mi><mml:mo>\u2264<\/mml:mo><mml:mn>.05<\/mml:mn><\/mml:mrow><\/mml:math>) greater improvement on brief pain inventory-Interference ratings. Patient global impression of improvement ratings were superior to placebo (<mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M3\"><mml:mrow><mml:mi>P<\/mml:mi><mml:mo>\u2264<\/mml:mo><mml:mn>.01<\/mml:mn><\/mml:mrow><\/mml:math>) for duloxetine patients in all placebo-controlled studies. Response rates (based on 30% pain reduction) ranged from 57% to 68% for duloxetine and from 35% to 47% for placebo and were statistically significantly different (<mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M4\"><mml:mrow><mml:mi>P<\/mml:mi><mml:mo>\u2264<\/mml:mo><mml:mn>.01<\/mml:mn><\/mml:mrow><\/mml:math>) between treatment groups in 3 out of 4 studies. The open-label study showed maintenance of analgesic effect of duloxetine in DPNP. In the duloxetine groups, 4.3% to 14.9% of patients discontinued because of adverse events (placebo groups: 2.6% to 7.4%). Most commonly reported treatment-emergent adverse events were nausea, somnolence, and headache. Duloxetine 40 and 60 mg QD was efficacious and well tolerated in the management of DPNP.<\/jats:p>","DOI":"10.1155\/2012\/898347","type":"journal-article","created":{"date-parts":[[2012,8,29]],"date-time":"2012-08-29T21:02:36Z","timestamp":1346274156000},"page":"1-12","source":"Crossref","is-referenced-by-count":3,"title":["Review of Efficacy and Safety of Duloxetine 40 to 60\u2009mg Once Daily in Patients with Diabetic Peripheral Neuropathic Pain"],"prefix":"10.1155","volume":"2012","author":[{"given":"Vladimir","family":"Skljarevski","sequence":"first","affiliation":[{"name":"Department of Neuroscience, Eli Lilly and Company, Indianapolis, IN 46285, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elijah P.","family":"Frakes","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Eli Lilly and Company, Indianapolis, IN 46285, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doron","family":"Sagman","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Eli Lilly Canada, Toronto, ON, Canada M1N 2E8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lipsius","sequence":"additional","affiliation":[{"name":"Department of Strategic Resourcing, PharmaNet\/i3, Ann Arbor, MI 48108, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra N.","family":"Heinloth","sequence":"additional","affiliation":[{"name":"Department of Strategic Resourcing, PharmaNet\/i3, Ann Arbor, MI 48108, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9ctor J.","family":"Due\u00f1as Tentori","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Eli Lilly de M\u00e9xico, 03900 M\u00e9xico, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.183"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60679-X"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2011.05.034"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2006.00179.x"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2007.00164.x"},{"issue":"1","key":"6","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0022-3565(25)38657-X","volume":"269","year":"1994","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/npp.1993.4","volume":"8","year":"1993","journal-title":"Neuropsychopharmacology"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1097\/01.yic.0000224782.83287.3c"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.2174\/1381612053764805"},{"key":"10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1146\/annurev.ne.14.030191.001251","volume":"14","year":"1991","journal-title":"Annual Review of Neuroscience"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.2741\/3585"},{"key":"12","year":"2011"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2005.03.029"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000240225.04000.1a"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2005.00061.x"},{"key":"16","volume-title":"HMFX: a study for the treatment of diabetic peripheral neuropathic pain","year":"2010"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.1000"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1111\/j.2040-1124.2010.00073.x"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.12.002"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.2174\/157488609787354404"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2007.00276.x"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2007.09.005"},{"key":"24","volume-title":"HMEM: maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain (DPNP)","year":"2010"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0366-6999.2010.22.003"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.5.1.157"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X162719"}],"container-title":["Pain Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/archive\/2012\/898347.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/archive\/2012\/898347.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/archive\/2012\/898347.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T13:40:30Z","timestamp":1744033230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/prt\/2012\/898347\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,29]]},"references-count":26,"alternative-id":["898347","898347"],"URL":"https:\/\/doi.org\/10.1155\/2012\/898347","relation":{},"ISSN":["2090-1542","2090-1550"],"issn-type":[{"value":"2090-1542","type":"print"},{"value":"2090-1550","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,29]]}}}